sorafenib has been researched along with 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole) | Trials (3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole) | Recent Studies (post-2010) (3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 377 | 2 | 154 |
| Protein | Taxonomy | sorafenib (IC50) | 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole (IC50) |
|---|---|---|---|
| Histone acetyltransferase p300 | Homo sapiens (human) | 1.3 | |
| Hypoxia-inducible factor 1-alpha | Homo sapiens (human) | 2.935 | |
| CREB-binding protein | Homo sapiens (human) | 1.3 | |
| Endothelial PAS domain-containing protein 1 | Homo sapiens (human) | 1.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, S; Gao, J; Gu, F; Ke, S; Kong, F; Kong, J; Pan, B; Shen, Q; Sun, H; Sun, W; Zhang, Q; Zheng, L | 1 |
1 other study(ies) available for sorafenib and 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole
| Article | Year |
|---|---|
YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Immunohistochemistry; Indazoles; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Sorafenib; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2014 |